- Home
- WERN vs GERN Comparison
WERN vs GERN Comparison
Compare WERN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- GERN
- Stock Information
- Founded
- WERN 1956
- GERN 1990
- Country
- WERN United States
- GERN United States
- Employees
- WERN N/A
- GERN N/A
- Industry
- WERN Trucking Freight/Courier Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- GERN Health Care
- Exchange
- WERN Nasdaq
- GERN Nasdaq
- Market Cap
- WERN 2.3B
- GERN 2.5B
- IPO Year
- WERN N/A
- GERN 1996
- Fundamental
- Price
- WERN $39.30
- GERN $4.02
- Analyst Decision
- WERN Hold
- GERN Strong Buy
- Analyst Count
- WERN 16
- GERN 10
- Target Price
- WERN $37.31
- GERN $6.95
- AVG Volume (30 Days)
- WERN 714.3K
- GERN 10.0M
- Earning Date
- WERN 10-29-2024
- GERN 11-07-2024
- Dividend Yield
- WERN 1.43%
- GERN N/A
- EPS Growth
- WERN N/A
- GERN N/A
- EPS
- WERN 0.73
- GERN N/A
- Revenue
- WERN $3,097,524,000.00
- GERN $29,480,000.00
- Revenue This Year
- WERN N/A
- GERN $30,930.80
- Revenue Next Year
- WERN $4.13
- GERN $315.72
- P/E Ratio
- WERN $53.70
- GERN N/A
- Revenue Growth
- WERN N/A
- GERN 9199.68
- 52 Week Low
- WERN $33.12
- GERN $1.64
- 52 Week High
- WERN $43.26
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- WERN 52.41
- GERN 48.45
- Support Level
- WERN $38.56
- GERN $3.60
- Resistance Level
- WERN $42.48
- GERN $3.86
- Average True Range (ATR)
- WERN 1.01
- GERN 0.22
- MACD
- WERN -0.15
- GERN -0.00
- Stochastic Oscillator
- WERN 41.54
- GERN 46.67
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - TTS and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.